Transitioning liquid biopsies from research to practice in lung cancer
Addressing cost and affordability issues is now key to increasing the use of this approach in the clinical setting in Asia
Performance data from AI tools show progress in oncology
Cancer imaging and identification of predictive biomarkers are the best performed tasks reported in studies presented at ESMO Congress 2023
Molecular characterisation of Ewing sarcomas could provide new treatment options for a patient subset
Activating EZH2 mutations may define a new subset of aggressive Ewing sarcomas that benefit from treatment with an EZH2 inhibitor
Molecular profiling of neuroendocrine neoplasms reveals markers with prognostic and therapeutic relevance
A Spanish study describes the genomic characterisation of neuroendocrine neoplasms as the first step towards more personalised management
Sinonasal cancer: whole-exome sequencing reveals potential therapeutic targets
Results from a study suggest that some existing inhibitors may benefit all subtypes of these rare malignancies, which currently lack effective treatments
New tools and methods are discussed for optimising investigation of precision therapeutics
Results of extensive genomic profiling and a Time-to-Event Continual Reassessment Method show some promise in investigating new treatments and targets in early-phase trials, despite not being ready for routine research
NGS – a weapon in molecular pathology?
Next generation sequencing has revolutionised cancer management, but has also raised some issues that have yet to be addressed
A study reveals the clonal heterogeneity of de novo metastatic castration-sensitive prostate cancer
Findings suggest that analysis of multiple prostate diagnostic biopsy cores, in contrast to frequent practice, may help reduce tumour mischaracterisation and identify genetic alterations relevant to personalised treatment
Combining liquid biopsy technologies may help improve tumour monitoring
Results from two studies suggest that this approach is essential to refining liquid biopsy use in early cancer detection and to check tumour progression
Should cancer therapy be tailored based on receptor tyrosine kinase alterations?
Data from a molecular analysis of receptor tyrosine kinase-mutated cancers show a wide heterogeneity of alterations and response to tyrosine kinase inhibitor monotherapy